Partner: Paul Jones Adam


Recent publications
1.Gregory Grace E., Haley Michael J., Jones Adam P., Hannan C., Evans D. G., King Andrew T., Paszek P., Pathmanaban Omar N., Couper Kevin N., Brough D., Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma, Brain Communications, ISSN: 2632-1297, DOI: 10.1093/braincomms/fcae400, Vol.6, No.6, pp.1-14, 2024
Abstract:

The variability in vestibular schwannoma growth rates greatly complicates clinical treatment. Management options are limited to radiological observation, surgery, radiotherapy and, in specific cases, bevacizumab therapy. As such, there is a pressing requirement for growth restricting drugs for vestibular schwannoma. This study explored potential predictors of vestibular schwannoma growth in depth, highlighting differences between static and growing vestibular schwannoma to identify potential therapeutic targets. High-dimensional imaging was used to characterize the tumour micro-environment of four static and five growing vestibular schwannoma (indicated by volumetric change < 20% or ≥ 20% per year, respectively). Single-cell spatial information and protein expression data from a panel of 35 tumour immune-targeted antibodies identified specific cell populations, their expression profiles and their spatial localization within the tumour micro-environment. Growing vestibular schwannoma contained significantly more proliferative and non-proliferative alternatively activated tumour-associated macrophages per millimetre square compared with static vestibular schwannoma. Furthermore, two additional proliferative cell types were identified in growing and static vestibular schwannoma: transitioning monocytes and programmed cell death ligand 1 (PD-L1+) Schwann cells. In agreement, growing vestibular schwannoma was characterized by a tumour micro-environment composed of immune-enriched, proliferative neighbourhoods, whereas static vestibular schwannoma were composed of tumour-enriched, non-proliferative neighbourhoods. Finally, classically activated macrophages significantly colocalized with alternatively activated macrophages in static vestibular schwannoma, but this sequestration was reduced in growing vestibular schwannoma. This study provides a novel, spatial characterization of the immune landscape in growing vestibular schwannoma, whilst highlighting the need for new therapeutic targets that modulate the tumour immune micro-environment.

Keywords:

tumour-associated macrophage, inflammation, tumour micro-environment, vestibular schwannoma, acoustic neuroma

Affiliations:
Gregory Grace E.-other affiliation
Haley Michael J.-other affiliation
Jones Adam P.-other affiliation
Hannan C.-other affiliation
Evans D. G.-other affiliation
King Andrew T.-other affiliation
Paszek P.-IPPT PAN
Pathmanaban Omar N.-other affiliation
Couper Kevin N.-other affiliation
Brough D.-other affiliation
2.Gregory Grace E., Jones Adam P., Haley Michael J., Hoyle C., Zeef Leo A. H., Lin I., Coope David J., King Andrew T., Evans D. G., Paszek P., Couper Kevin N., Brough D., Pathmanaban Omar N., The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma, Brain Communications, ISSN: 2632-1297, DOI: 10.1093/braincomms/fcad197, Vol.5, No.4, pp.1-15, 2023
Abstract:

Bilateral vestibular schwannoma is the hallmark of NF2-related schwannomatosis, a rare tumour predisposition syndrome associated with a lifetime of surgical interventions, radiotherapy and off-label use of the anti-angiogenic drug bevacizumab. Unilateral vestibular schwannoma develops sporadically in non-NF2-related schwannomatosis patients for which there are no drug treatment options available. Tumour-infiltrating immune cells such as macrophages and T-cells correlate with increased vestibular schwannoma growth, which is suggested to be similar in sporadic and NF2-related schwannomatosis tumours. However, differences between NF2-related schwannomatosis and the more common sporadic disease include NF2-related schwannomatosis patients presenting an increased number of tumours, multiple tumour types and younger age at diagnosis. A comparison of the tumour microenvironment in sporadic and NF2-related schwannomatosis tumours is therefore required to underpin the development of immunotherapeutic targets, identify the possibility of extrapolating ex vivo data from sporadic vestibular schwannoma to NF2-related schwannomatosis and help inform clinical trial design with the feasibility of co-recruiting sporadic and NF2-related schwannomatosis patients. This study drew together bulk transcriptomic data from three published Affymetrix microarray datasets to compare the gene expression profiles of sporadic and NF2-related schwannomatosis vestibular schwannoma and subsequently deconvolved to predict the abundances of distinct tumour immune microenvironment populations. Data were validated using quantitative PCR and Hyperion imaging mass cytometry. Comparative bioinformatic analyses revealed close similarities in NF2-related schwannomatosis and sporadic vestibular schwannoma tumours across the three datasets. Significant inflammatory markers and signalling pathways were closely matched in NF2-related schwannomatosis and sporadic vestibular schwannoma, relating to the proliferation of macrophages, angiogenesis and inflammation. Bulk transcriptomic and imaging mass cytometry data identified macrophages as the most abundant immune population in vestibular schwannoma, comprising one-third of the cell mass in both NF2-related schwannomatosis and sporadic tumours. Importantly, there were no robust significant differences in signalling pathways, gene expression, cell type abundance or imaging mass cytometry staining between NF2-related schwannomatosis and sporadic vestibular schwannoma. These data indicate strong similarities in the tumour immune microenvironment of NF2-related schwannomatosis and sporadic vestibular schwannoma.

Keywords:

tumour microenvironment, vestibular schwannoma, tumour-associated macrophages, NF2, NF2-related schwannomatosis

Affiliations:
Gregory Grace E.-other affiliation
Jones Adam P.-other affiliation
Haley Michael J.-other affiliation
Hoyle C.-other affiliation
Zeef Leo A. H.-other affiliation
Lin I.-other affiliation
Coope David J.-other affiliation
King Andrew T.-other affiliation
Evans D. G.-other affiliation
Paszek P.-IPPT PAN
Couper Kevin N.-other affiliation
Brough D.-other affiliation
Pathmanaban Omar N.-other affiliation